QuidelOrtho looks past the post-pandemic slump by pushing into faster, near-patient testing and expanding in places where modern diagnostics are still underused. The upside hinges on smoother integration of new technology and better execution, while pricing pressure and stale products could keep results stuck.Read more
QuidelOrtho is cutting costs faster than expected and pushing deeper into everyday testing that hospitals and clinics rely on, even as the COVID testing boom fades. New products and a China expansion could reignite growth, but integration headaches and tough competition may still weigh on results.Read more
Key Takeaways Cost pressures and shifting reimbursement trends threaten long-term revenue growth and margin expansion, despite rising global demand for advanced diagnostics and planned operational improvements. Expansion into underpenetrated and emerging markets is challenged by government price controls and aggressive local competition, constraining sustainable revenue and margin gains.Read more
No trending discussion available.
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
